2022年11月17日,

風險資本新聞|私人股本風險資本目錄|私人股本目錄風險資本公司列表/風險資本和私人股本公司和出版來源自1998年以來,VCPro數據庫是最可靠的、最新的和負擔得起的風險資本目錄2022最新更新版現在可用!(2022年7月更新)VCPro數據庫2022年25日版-一個可下載的和可搜索的數據庫與風險資本6800 +全球風險資本和私人股本公司。最可靠的、最新的和負擔得起的風險資本的目錄。VCPro數據庫可以在Windows和macOS版本。自1998年以來,它已經出版。Torigen製藥宣布完成1300萬美元的籌資法明頓,康涅狄格州,11月16日,2022年,Torigen製藥、公司,commercial-stage動物衛生生物製劑公司今天宣布,它已關閉了1300萬美元的A1輪Werth家人投資夥伴,有限責任公司和康涅狄格創新,Inc .,使總提出的公司1800萬美元。現有投資者翡翠開發經理、Gaingels Kema基金,聖母院大學SoGal Ventures和康州大學創新基金,公司參與了一輪。在這一輪新投資者還包括硬木資本和資本優勢。“我們的目標是創建一個獸醫行業首個腫瘤工具箱,”阿什利Kalinauskas說,首席執行官和共同創始人Torigen藥品。“這輪融資將使我們能夠繼續開發新產品,利用我們的管道。 We are excited to work with all our investors as we expand our platform and continue to help the millions of pets diagnosed with cancer and other immune-mediated diseases each year.” “Our investment in Torigen is grounded in the same values and principles that guide us at Werth Ventures,” said Musan Duric, Investment Portfolio Manager, Werth Ventures. “As a family office, we focus on growing the good in business and life, supporting women entrepreneurs, and championing change within the animal health market. Torigen’s lead product, VetiVax, is a prime example of the company’s ability to deliver innovative products and access the veterinary market. We’re committed to seeing Torigen succeed and look forward to accompanying the entire team on its journey.” “Torigen is a transformative animal health tech company that creates personalized cancer immunotherapies, making effective cancer treatment more accessible and affordable for pet owners,” said Neil Cohen, Chairman, Emerald Development Managers. “The work Torigen has done to date is exceptional. The team has developed a deep understanding of animal oncology, allowing them to develop new treatments to cover additional animal health conditions. We look forward to supporting Torigen’s growth and to collaborating with Connecticut Innovations, Werth, and all those invested in the company’s success.” To meet the market’s strong demand, Torigen is now recruiting a skilled salesforce. Postings for open roles can be found at http://www.torigen.com. About Torigen Pharmaceuticals Inc: Torigen is transforming pet cancer treatment by harnessing the pet's immune system to create personalized cancer immunotherapies, making pet cancer treatment more accessible and more affordable. Torigen recognizes the instrumental role pets play in our families and is determined to extend the lives of companion animals despite a cancer diagnosis. With over 50% of all dogs over the age of 10 dying from cancer, Torigen is dedicated to providing affordable and effective cancer care solutions for all companion animals. Torigen is a spin-out from the University of Notre Dame and backed by Werth Family Investment Associates, Connecticut Innovations, Emerald Development Managers, Ironwood Capital, Advantage Capital, The University of Connecticut, The University of Notre Dame, SoGal Ventures, Gaingels, and other prominent investors. For more information visit http://www.torigen.com.